COMPANY PROFILE

Vilya

Explore full profile

Developing a novel class of drugs that precisely target the biology of disease

Seattle, United StatesFounded 2022Biotech & Life Sciences

Valuation $250–500M Last recorded · 2024

Headcount <100 Current team size

Total funding $50–100M Disclosed equity funding

Unlock exact values

About Vilya

Vilya is a computational biotechnology company developing a new class of medicines.

The company's platform is based on research from the Institute of Protein Design and utilizes advanced computational methods for drug design. This technology enables the creation of novel medicines that can precisely target the biological basis of diseases.

Vilya has secured significant investment, recently expanding its Series A financing to $71 million. This capital is intended to advance the development of its computational platform and accelerate its pipeline of therapeutic candidates. The business model focuses on creating a new class of medicines to address a range of diseases, potentially through internal development or partnerships within the pharmaceutical industry.

MoreLess Source: Dealroom company data

At a glance

Status: Operational
Founded: 2022
Headquarters: Seattle, United States
Employees: 48
Open positions: 3
Dealroom signal: 73.1/100
Industry: Health
Sub-industry: Pharmaceutical, BioTechnology
Sector: Biotech & Life Sciences, Biotechnology, Drug Development, Core AI, Spinout, Biotech and Pharma, Generative AI, AI Drug Discovery
Technology: Artificial Intelligence, Deep Tech
Business model: Manufacturing
Client focus: b2b
Links: Website LinkedIn

Knowledge graph

News, research, reports and resources connected to this company by Dealroom

Funding history

3 recorded events

Company financing events and reported valuations.

Deal type	Date	Amount	Valuation	Investors	Source
SERIES AOther financing	Jun 2024	$21M	$250M	Menlo Ventures · Altitude Life Science Ventures · NVentures · Madrona Venture Group	↗
SERIES AOther financing	Aug 2022	$50M	$200M	ARCH Venture Partners	↗

Showing the latest 2 of 3 recorded eventsBook a demo for the full funding history →

Growth signals

Vilya website traffic

Latest recorded traffic for Vilya is 3.2K monthly website visits, down 67% over the last three months. Vilya's team declined 2% over the past year.

Latest monthly visits3.2K 3-month web change-67% 1-year team growth-2%

Monthly website visitsOct 2022–Jun 2026

Explore monthly traffic historyTrack growth over time and compare with peersBook a demo

Summary metrics are public; monthly history is available with a demoCompare with peers →

Open positions

Openings linked to this company in Dealroom

Deep Learning ScientistSeattle, Washington, United States · Data Science & Engineering · Jan 9, 2026 Deep Learning InternSeattle, Washington, United States · Data Science & Engineering · Jan 9, 2026 Scientist - Macrocycle DesignSeattle, Washington, United States · Design · Jan 9, 2026

3 distinct openings shownExplore hiring signals →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Company	Headquarters	Status	Employees	Total funding	Valuation
PBProxima BioFormerly VantAI. Proximity therapeutics hijacking cellular machinery for protein degradation	New York City, United States	Operational	77	$80M	$320M
STScripta TherapeuticsAI-driven drug discovery modulating transcription factor activity	Oxford, United Kingdom	Operational
XTXaira TherapeuticsIntegrated biotechnology company focusing on leveraging artificial intelligence to transform drug discovery and development	Brisbane, United States	Operational
MTMETiS TherapeuticsAI-driven platform for drug discovery and delivery	Cambridge, United States	Operational
BIBioSimulyticsIn-silico drug development for API small molecules ⚛️	Dublin, Ireland	Operational
SBSibylla BiotechFacing the complexity of drug discovery with the power of an innovative approach for meeting unmet medical needs	Bresso, Italy	Operational
AQAqemiaUsing quantum-physics with AI to speed up the discovery of novel drug molecules	Paris, France	Operational
EBEvaxion BiotechPioneering discovery of antigens and neo-epitopes for vaccines and antibodies using artificial intelligence	Hørsholm, Denmark	Operational